press

MEDIPOST is a special biotechnology company in studying and manufacturing stem cell drugs and umbilical cord blood.
113 2 팔로워
소이현-인교진 부부도 자녀 제대혈 보관 동참

소이현-인교진 부부도 자녀 제대혈 보관 동참

소이현-인교진 부부도 자녀 제대혈 보관 동참

소이현-인교진 부부도 자녀 제대혈 보관 동참

MEDIPOST, achieves ‘150 patent applications and 50 patent registrations’

MEDIPOST, achieves ‘150 patent applications and 50 patent registrations’

Administration of lung disease medicine Pneumostem started in U.S. clinical trial

Administration of lung disease medicine Pneumostem started in U.S. clinical trial

Administration of lung disease medicine Pneumostem started in U.S. clinical trial

Administration of lung disease medicine Pneumostem started in U.S. clinical trial

Core dementia treatment technology patented at 6 European countries, concurrently

Core dementia treatment technology patented at 6 European countries, concurrently

Administration of lung disease medicine ‘Pneumostem’ in clinical trial completed

Administration of lung disease medicine ‘Pneumostem’ in clinical trial completed

Nikkei Japan Reports the Status of MEDIPOST’s Stem Cell Research

Nikkei Japan Reports the Status of MEDIPOST’s Stem Cell Research

Singapore/Taiwan consecutively invited MEDIPOST to its stem cell forums

Singapore/Taiwan consecutively invited MEDIPOST to its stem cell forums

Stem cell cosmetics extending to China

Stem cell cosmetics extending to China

Pinterest
검색